Treatment of Sequelae Caused by Severe Brain Injury With Autologous Adipose-derived Mesenchymal Stem Cells
NCT ID: NCT01649700
Last Updated: 2014-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
1 participants
INTERVENTIONAL
2011-10-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells
NCT01649687
Mesenchymal Stem Cells in Central Nervous System injury2017
NCT03291366
Injectable Collagen Scaffold™ Combined With MSCs Transplantation for Brain Injury
NCT02767817
Functional Recovery Effect of Bloodletting Puncture at Jing-well Points on Acute Brain Injury Patients
NCT04930146
Transcranial Magnetic Stimulation in the Rehabilitation of Postoperative Motor Dysfunction.
NCT04706338
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mesenchymal stem cells treatment
All subjects will receive autologous adipose-derived mesenchymal stem cells
autologous adipose-derived mesenchymal stem cells
Patients will receive five infusions, one month apart, each comprising 5-7x10\^7 cells of autologous adipose-derived mesenchymal stem cells.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
autologous adipose-derived mesenchymal stem cells
Patients will receive five infusions, one month apart, each comprising 5-7x10\^7 cells of autologous adipose-derived mesenchymal stem cells.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stroke-like symptoms, including paralysis, caused by brain AVM hemorrhage.
* Subject's modified Rankin scale (mRS) grades IV\~V.
* Ages between 20\~40 years.
* Estimated life expectancy must be greater than 2 months.
* Signed informed consent from the subject.
Exclusion Criteria
* Subject infected with hepatitis C, HIV or syphilis.
* Subject not suitable for liposuction surgery.
* Subject not eligible for PET or MRI.
* Subject enrolled in any other cell therapy studies within the past 30 days.
* Subject deemed to be not suitable for the study by the investigator.
20 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Yang Ming Chiao Tung University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oscar Kuang-Sheng Lee
Director of Stem Cell Research Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taipei Veterans General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SB-VGH-201101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.